Drug Interaction Report

Consumer information for this interaction is not currently available.

MONITOR: Coadministration with inhibitors of CYP450 2D6 may increase the plasma concentrations of topical sofpironium, which has been shown to be partially metabolized by the isoenzyme. In a pharmacokinetic study in patients with primary axillary hyperhidrosis, sofpironium systemic exposure (AUC) and peak plasma concentration (Cmax) increased approximately 2-fold following concomitant use with the potent CYP450 2D6 inhibitor paroxetine at a 20 mg oral dose. Clinical data for sofpironium use in combination with other less potent CYP450 2D6 inhibitors are not available.

MANAGEMENT: Caution is advised when sofpironium topical is used concurrently with CYP450 2D6 inhibitors. Patients should be more closely monitored for adverse effects such as blurred vision, urinary retention, difficulty controlling body temperature in warm environments, and dry mouth.

Do not consume grapefruit, grapefruit juice, star fruit, pomegranate, or pomegranate juice during treatment with panobinostat. Doing so can increase blood levels of the medication. You may be more likely to experience side effects such as nausea; vomiting; diarrhea; loss of appetite; fatigue; swelling in the arms or legs; heart problems (e.G., chest pain, heart failure, irregular heartbeat); liver problems; and impaired bone marrow function resulting in low numbers of different types of blood cells, which can increase the risk of anemia, bleeding problems, and infections. Talk to your doctor if you have any questions or concerns. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.